These TRAIL formulations include highly stable TRAIL trimers [3,27], fusion proteins with single-chain variable antibody fragments (scFv) that active target TRAIL to cancer cells [28,29,30,31] or immune cells [32,33], mutant variants with specificity to DR5 [34,35], and different types of nanoparticles [36,37,38,39,40,41,42]. Here, TNFSF10 is linked to cancer.